American journal of respiratory and critical care medicine · 2026
Association of a polygenic risk score with diagnosis and outcomes in idiopathic pulmonary fibrosis.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kalra Sean S, Grilli Christopher B, Coombes Brandon J, Armasu Sebastian, Upjohn David P, Egan Jan B, Chen Qingwen, Tern Courtney, Zhang Chengyue, Rose Jonathan A, Putman Rachel, Mcdermott Greg, Hsieh Yuli L, Bublitz Michele L, Carmona Eva M, Klee Eric W, Lazaridis Konstantinos N, Lasky-Su Jessica, Dudbridge Frank, Peljto Anna L, Schwartz David A, Silverman Edwin K, Allen Richard J, Olson Janet, Walker T'Nita, Wain Louise V, Zamora Ana, Zein Joe G, Hunninghake Gary M, Tapestry Cohort, Ortega Victor E, Moll Matthew, Cho Michael H
Аннотация
RATIONALE: Idiopathic pulmonary fibrosis (IPF) is characterized by chronic progressive pulmonary fibrosis and high mortality. Genetic markers, summarized into a polygenic risk score (PRS), associate with IPF in well-phenotyped research cohorts.
OBJECTIVES: To evaluate the performance of the PRS using real-world data from routinely captured electronic health care records.
METHODS: We conducted an observational study evaluating the association of a PRS for IPF with electronic health care record diagnosis of IPF as well as lung transplant-free survival in 4 independent cohorts: the Mass General Brigham Biobank (MGBB), Mayo Clinic Biobank (MCBB), Mayo Clinic Tapestry Cohort (Tapestry), and U.K. Biobank (UKBB). We used multivariable logistic regression and multivariable Cox proportional hazards models adjusting for age, gender, and principal components of ancestry. The cohorts then underwent fixed and random effects meta-analysis.
MEASUREMENTS AND MAIN RESULTS: Of 37 709, 44 195, 43 202, and 447 422 participants from MGBB, MCBB, Tapestry, and UKBB, respectively, 1015 (2.7%), 2879 (6.5%), 1310 (3.0%), and 2742 (0.6%) participants had an IPF diagnosis. Meta-analysis demonstrated a high-risk PRS associated with IPF diagnosis (odds ratio [OR] = 2.88; 95% CI, 2.41-3.44) compared to all other individuals. A high-risk PRS also associated with the composite endpoint of mortality or lung transplant among those with an IPF diagnosis (hazard ratio [HR] = 1.23; 95% CI, 1.11-1.35) compared to all other individuals.
CONCLUSIONS: A PRS can identify those at risk for an IPF diagnosis and mortality in biobank-scale data, which may have implications for clinical decisions. Further work is necessary to evaluate the utility of adding genetics in clinical settings.
OBJECTIVES: To evaluate the performance of the PRS using real-world data from routinely captured electronic health care records.
METHODS: We conducted an observational study evaluating the association of a PRS for IPF with electronic health care record diagnosis of IPF as well as lung transplant-free survival in 4 independent cohorts: the Mass General Brigham Biobank (MGBB), Mayo Clinic Biobank (MCBB), Mayo Clinic Tapestry Cohort (Tapestry), and U.K. Biobank (UKBB). We used multivariable logistic regression and multivariable Cox proportional hazards models adjusting for age, gender, and principal components of ancestry. The cohorts then underwent fixed and random effects meta-analysis.
MEASUREMENTS AND MAIN RESULTS: Of 37 709, 44 195, 43 202, and 447 422 participants from MGBB, MCBB, Tapestry, and UKBB, respectively, 1015 (2.7%), 2879 (6.5%), 1310 (3.0%), and 2742 (0.6%) participants had an IPF diagnosis. Meta-analysis demonstrated a high-risk PRS associated with IPF diagnosis (odds ratio [OR] = 2.88; 95% CI, 2.41-3.44) compared to all other individuals. A high-risk PRS also associated with the composite endpoint of mortality or lung transplant among those with an IPF diagnosis (hazard ratio [HR] = 1.23; 95% CI, 1.11-1.35) compared to all other individuals.
CONCLUSIONS: A PRS can identify those at risk for an IPF diagnosis and mortality in biobank-scale data, which may have implications for clinical decisions. Further work is necessary to evaluate the utility of adding genetics in clinical settings.